MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.870
-0.080
-2.71%
Opening 14:38 02/26 EST
OPEN
2.870
PREV CLOSE
2.950
HIGH
2.960
LOW
2.695
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
1.530
MARKET CAP
138.68M
P/E (TTM)
-2.4386
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Zacks · 3h ago
Otonomy to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company...
GlobeNewswire · 1d ago
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
Zacks.com · 1d ago
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
Zacks.com · 1d ago
Otonomy (OTIC) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Otonomy (OTIC) yesterday and set a price target of $5.50. The company's shares closed last
SmarterAnalyst · 2d ago
Otonomy (OTIC) Gets a Buy Rating from H.C. Wainwright
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Otonomy (OTIC) yesterday and set a price target of $5.50. The company's shares closed last
SmarterAnalyst · 2d ago
DJ Otonomy Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
DJ Otonomy Price Target Cut to $5.50/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTIC. Analyze the recent business situations of Otonomy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OTIC stock price target is 5.38 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 35.73M
% Owned: 73.94%
Shares Outstanding: 48.32M
TypeInstitutionsShares
Increased
22
3.06M
New
29
51.97K
Decreased
22
3.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.52%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Independent Director
Jay Lichter
President/Chief Executive Officer/Director
David Weber
Chief Financial Officer
Paul Cayer
Chief Technology Officer
Robert Savel
Independent Director
James Breitmeyer
Independent Director
Vickie Capps
Independent Director
Ciara Kennedy
Independent Director
Iain McGill
Independent Director
Theodore Schroeder
  • Dividends
  • Splits
  • Insider Activity
No Data
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.